JP Morgan Maintains Overweight on Xenon Pharmaceuticals, Raises Price Target to $82

Benzinga Newsdesk www.benzinga.com Positive 82.4%

Neg 0% Neu 0% Pos 82.4%

JP Morgan analyst Tessa Romero maintains Xenon Pharmaceuticals (NASDAQ:XENE) with a Overweight and raises the price target from $80 to $82.